A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and
Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction
with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of
Patients with Extensive Stage Small-Cell Lung Cancer.